{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T07:40:37Z","timestamp":1781595637193,"version":"3.54.5"},"reference-count":19,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T00:00:00Z","timestamp":1654128000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Erythema multiforme (EM) is a muco\u2010cutaneous inflammatory disease mainly triggered by herpes simplex virus (HSV) recurrences. Association of EM and circulating auto\u2010antibodies against plakins (anti\u2010PLK\u2010Abs [EM\u2010PLK+]) has been reported. However, little is known about this subset of EM.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>We aimed to describe the clinical and immunological features and response to treatment of EM\u2010PLK+.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a retrospective multicentric study of EM\u2010PLK+ selected from the database of the immunological laboratory of Bichat hospital, Paris, France, from January 2009 to December 2020. Anti\u2010PLK\u2010Abs were detected in \u22651 immunological tests: immunofluorescence assay, immunoblotting and\/or ELISA. Patients with alternative diagnoses were excluded.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We included 29 patients (16 women, median age 25 [range 2\u201358] years). EM\u2010PLK+ were mostly major (EM with \u22652 mucosal involvements; <jats:italic>n<\/jats:italic>\u2009=\u200924, 83%) and relapsing (\u22652 flares; <jats:italic>n<\/jats:italic>\u2009=\u200923, 79%). Cutaneous lesions were target (<jats:italic>n<\/jats:italic>\u2009=\u200913, 54%) and target\u2010like lesions (<jats:italic>n<\/jats:italic>\u2009=\u20099, 38%) with usual topography (acral, <jats:italic>n<\/jats:italic>\u2009=\u200919, 79%; limbs, <jats:italic>n<\/jats:italic>\u2009=\u200921, 88%). Mucosal lesions affected the mouth (<jats:italic>n<\/jats:italic>\u2009=\u200927, 96%) and genitalia (<jats:italic>n<\/jats:italic>\u2009=\u200919, 68%), with a median of 2 [range 0\u20135] mucous membranes. EM\u2010PLK+ were suspected as certain or possible postherpetic (EM\u2010HSV) in 19 cases (65.5%); no triggering factors were detected in 9 (31%) patients. Desmoplakin\u2010I\/II Abs were the most frequent anti\u2010PLK\u2010Abs (<jats:italic>n<\/jats:italic>\u2009=\u200920, 69%); envoplakin and periplakin Abs were detected in 11 and 9 cases. Relapsing EM\u2010PLK+ (<jats:italic>n<\/jats:italic>\u2009=\u200923) were still active (\u22651 flare within 6\u2009months) in 13 (57%) patients despite immunosuppressive therapy (<jats:italic>n<\/jats:italic>\u2009=\u20098, 62%). Antiviral drugs were ineffective in preventing relapse in 15\/16 (94%) EM\u2010HSV.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The rationale for anti\u2010PLK\u2010Ab detection in EM is not elucidated. More systematic research of anti\u2010PLK\u2010Abs is warranted to better understand whether this association reflects humoral immune activity in a subset of EM or is fortuitous, related to an epitope spreading process. However, EM\u2010PLK+ seems to be associated with major and relapsing subtypes, and difficult\u2010to\u2010treat cases.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jdv.18259","type":"journal-article","created":{"date-parts":[[2022,5,24]],"date-time":"2022-05-24T08:01:26Z","timestamp":1653379286000},"page":"2438-2442","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Erythema multiforme associated with anti\u2010plakin antibodies: a multicentric retrospective case series"],"prefix":"10.1111","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5613-2745","authenticated-orcid":false,"given":"A.","family":"Weill","sequence":"first","affiliation":[{"name":"Department of Dermatology CHU Henri Mondor, AP\u2010HP  Cr\u00e9teil France"},{"name":"Referral Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL  Cr\u00e9teil France"},{"name":"Referral Center for Auto\u2010Immune Bullous Diseases (MALIBUL), AP\u2010HP  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6043-6242","authenticated-orcid":false,"given":"V.","family":"Descamps","sequence":"additional","affiliation":[{"name":"Department of Dermatology CHU Bichat, AP\u2010HP  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2580-8607","authenticated-orcid":false,"given":"F.","family":"Chasset","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Department of Dermatology, CHU Tenon, AP\u2010HP Sorbonne Universit\u00e9  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5951-1831","authenticated-orcid":false,"given":"T.","family":"Mah\u00e9vas","sequence":"additional","affiliation":[{"name":"Department of Dermatology CHU Saint\u2010Louis, AP\u2010HP  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8531-9971","authenticated-orcid":false,"given":"I.","family":"Bourgault\u2010Villada","sequence":"additional","affiliation":[{"name":"Department of Dermatology CHU Ambroise Par\u00e9, AP\u2010HP  Boulogne Billancourt France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8194-457X","authenticated-orcid":false,"given":"P.","family":"Wolkenstein","sequence":"additional","affiliation":[{"name":"Department of Dermatology CHU Henri Mondor, AP\u2010HP  Cr\u00e9teil France"},{"name":"Referral Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL  Cr\u00e9teil France"},{"name":"Referral Center for Auto\u2010Immune Bullous Diseases (MALIBUL), AP\u2010HP  Paris France"},{"name":"Univ Paris Est Cr\u00e9teil Epiderm E  Cr\u00e9teil France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Chollet\u2010Martin","sequence":"additional","affiliation":[{"name":"Department of Immunobiology CHU Bichat, AP\u2010HP  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5383-7096","authenticated-orcid":false,"given":"S.","family":"Ingen\u2010Housz\u2010Oro","sequence":"additional","affiliation":[{"name":"Department of Dermatology CHU Henri Mondor, AP\u2010HP  Cr\u00e9teil France"},{"name":"Referral Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL  Cr\u00e9teil France"},{"name":"Referral Center for Auto\u2010Immune Bullous Diseases (MALIBUL), AP\u2010HP  Paris France"},{"name":"Univ Paris Est Cr\u00e9teil Epiderm E  Cr\u00e9teil France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6294-0052","authenticated-orcid":false,"given":"S.","family":"Grootenboer\u2010Mignot","sequence":"additional","affiliation":[{"name":"Referral Center for Auto\u2010Immune Bullous Diseases (MALIBUL), AP\u2010HP  Paris France"},{"name":"Department of Immunobiology CHU Bichat, AP\u2010HP  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,6,2]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(83)80003-6"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1995.01690170041005"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1998.02260.x"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199012203232503"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201001-0076OC"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12338566"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.181.1.169"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13313"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annder.2018.03.114"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2010.1150"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.12162"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.1998.00328.x"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2009.09566.x"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.06.046"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1159\/000074112"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12277397"},{"key":"e_1_2_6_18_1","article-title":"D\u00e9tection des Ac anti\u2010 envoplakine par ELISA : donn\u00e9es nouvelles dans l'\u00e9ryth\u00e8me polymorphe ?","author":"Mignot S","year":"2012","journal-title":"J Dermatol Paris"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1995.tb05024.x"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.4084"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.18259","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdv.18259","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.18259","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T16:13:49Z","timestamp":1692634429000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.18259"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,2]]},"references-count":19,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["10.1111\/jdv.18259"],"URL":"https:\/\/doi.org\/10.1111\/jdv.18259","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,2]]},"assertion":[{"value":"2021-12-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-02","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}